Sydney - Australia – Novotech, the largest biotech specialist CRO in the Asia-Pacific region, is now ranked in the top three CROs in South Korea for biotech IND approvals according to Ministry of Food and Drug Safety (MFDS) data.

Novotech made the announcement at South Korea’s KONECT International Conference. (Virtual-KST September 9-11) https://www.konectintconference.org/ 

The data came from a review of IND submissions over the past 12 months and is available on the MFDS portal https://nedrug.mfds.go.kr/searchClinic.

The other CROs in the top 3 were IQVIA and Syneos.

Novotech, which was recently awarded the Frost & Sullivan 2020 Frost & Sullivan Asia-Pacific CRO Company of the Year, also ranks ahead of several other global CROs for IND approvals.

Novotech’s Executive Director Asia Operations Yooni Kim said:

"The key to our IND success ranking is our strong local knowledge and presence. Knowing the local regulatory and clinical environment and guiding our clients through the process is how we achieve these outcomes for our biotech clients.

Since we stated operations in South Korea in 2007 we have conducted 130 clinical projects across all phases, and we now have over 80 staff in the Seoul office.

Novotech also received the Australian-Korean Business Excellence Award 2020 earlier this year in recognition of the team’s capabilities."

Novotech has signed 7 formal site partnerships with key hospitals in South Korea, including Seoul National University, Asan Medical Center, Yonsei University Severance Hospital, and Ulsan University Hospital, to facilitate the project management of clinical trials and accelerate biotech drug development (https://novotech-cro.com/locations).